Overview

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

BeiGene USA, Inc.
Massachusetts General Hospital
Roche-Genentech

Treatments:

Obinutuzumab
Venetoclax
Zanubrutinib